Celularity

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

Celularity, Inc. (CELU) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Celularity, Inc. (CELU) Is a Trending Stock: Facts to Know Before Betting on It

Celularity, Inc. (CELU) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Investors Heavily Search Celularity, Inc. (CELU): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Celularity, Inc. (CELU). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Celularity, Inc. (CELU) is a Trending Stock

Celularity, Inc. (CELU) is Attracting Investor Attention: Here is What You Should Know

Celularity's Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix

Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devi

Celularity's Pre-Request for Designation (Pre-RFD) is based on data showing  CTW contains 100 percent extracellular matrix

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Healt

Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum

Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

CH Trading Group will serve as exclusive territories distributor in 100-plus countries with US $225 million minimum purchase commitment Relationship opens access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products across the Middle East and the broader Islamic world FLORHAM PARK, N.J., RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia , Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement.

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

Celularity, Inc. (CELU) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -38.63% in 4 Weeks, Here's Why the Trend Might Reverse for Celularity, Inc. (CELU)

Legacy studies employing a single treatment course of  two infusions seven days apart demonstrated greatest benefit in three early studies

Celularity's Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn's Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

Veteran executive brings more than 30 years of biopharmaceutical public relations and public affairs experience Veteran executive brings more than 30 years of biopharmaceutical public relations and public affairs experience

Celularity Appoints Paul Graves as Chief Communications Officer

Celularity, Inc. (CELU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Celularity, Inc. (CELU)

Celularity, Inc. (CELU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Celularity, Inc. (CELU) Rating Upgrade to Strong Buy

FLORHAM PARK, N.J.--( BUSINESS WIRE )--Celularity Inc. (Nasdaq: CELU) (“Celularity” or “the “Company”), a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, today announced that it received Halal Certification of its business models, commercial stage biomaterial products, and clinical and investigational stage cellular therapeutic programs, indicating that they have undergone rigorous assessment to determine that they are permissible or acceptable in accordance with Islamic law or Sharia. The certificates were issued under the authority of Circle H International, Inc. (“Circle H”) and offer the Company the ability to serve Islamic markets globally. This announcement supports Celularity's global expansion strategy, which will ultimately include a presence in the Middle East North Africa (MENA) region and a priority focus on Saudi Arabia.

Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model

FLORHAM PARK, N.J.--( BUSINESS WIRE )--Celularity, Inc. (Nasdaq: CELU) (“Celularity” or “the Company”), a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, shared today that Chairperson, Founder and Chief Executive Officer Robert J. Hariri, M.D., Ph.D. addressed the Future Investment Initiative 6th Edition in Riyadh conference sponsored by the Future Investment Initiative (FII) at the plenary session: The Science and Technology for Extending Healthy Human Lifespan.

Celularity CEO Robert J. Hariri, M.D.

Down 35.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Celularity, Inc. (CELU)

Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 21.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Celularity, Inc. (CELU) Q3 Earnings Beat Estimates

SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, are pleased to announce that data from preclinical studies of Imugene's onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity's placental-derived off-the-shelf allogeneic CYCART-19 T cells was presented at the renowned Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held in Boston, USA on 8-12 November 2022.

Imugene's onCARlytics combination with Celularity's placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting

FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced financial results for the quarter ended September 30, 2022, and provided a corporate update.

Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it will present preclinical data on the development of its novel placental-derived allogeneic genetically modified natural killer (NK) cell therapy program CYNK-101 in combination with avelumab. Celularity will report its findings in a poster presentation at the 37th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) taking place in Boston, Massachusetts and virtually November 8-12, 2022.

Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer's 37th Annual Meeting

FLORHAM PARK, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies, announced the promotion of two senior executives and the formation of a new Executive Committee.

Celularity Promotes Two Executives in Executive Leadership Team

Veteran pharmaceutical executive brings more than 15 years of proven oncology and immunology experience Veteran pharmaceutical executive brings more than 15 years of proven oncology and immunology experience

Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A.

FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 11 a.m. ET.

Celularity to Present at Jefferies Cell and Genetic Medicine Summit

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced publication of a study in Frontiers in Immunology describing the antiviral role of its placental-derived natural killer (NK) cells (CYNK) in IAV infections.

Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

Camping World Hlds

FTC Solar

Dave & Buster's

Smith & Wesson Brands

Wheels Up Experience

Axcelis Technologies

September is living up to its reputation for being one of the worst months to own stocks.

News for Celularity Stock (CELU)